Results 21 to 30 of about 2,887 (179)
A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil. [PDF]
Sci Pharm, 2015 Drug product purity and potency are of most significance in the regulatory market as we notice many recalled batches worldwide, particularly in the US and Japan. Olmesartan Medoxomil is an anti-hypertensive drug.
Hanumantha Rao B +5 more
europepmc +2 more sources
Gingival overgrowth caused by Olmesartan Medoxomil: Observational study [PDF]
, 2019 Objective: Olmesartan Medoxomil is a type 1 receptor antagonist an antagonist of type 1 receptor (AT1) of angiotensin II (A-II) that inhibits numerous actions of A-II in the renin-angiotensin-aldosterone system (RAAS).
Andrea Di Lenarda +7 more
core +1 more source
Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function [PDF]
, 2009 WOS: 000269389400004PubMed: 19521888Serum cystatin C concentration is an alternative measure of kidney function that is less affected by age, sex or muscle mass, and is a more sensitive indicator of early renal dysfunction than creatinine-based ...
Ordu, Serkan +6 more
core +1 more source
Evaluation of the relative bioavailability between two formulations of olmesartan medoxomil 40mg, in orodispersible tablet form and coated tablet form, in healthy participants of both sexes [PDF]
Brazilian Journal of Pharmaceutical SciencesThe objective of this study was to verify whether the test formulation of olmesartan medoxomil, in orodispersible tablet form, administered with water (treatment B) and without water (treatment C), presents a rate and extent of absorption equivalent to ...
Guilherme Guimarães de Souza +7 more
doaj +1 more source
Hypertension: Focus on Olmesartan Medoxomil
, 2009 Hypertension is the leading cause of stroke, heart failure, and ischemic heart disease. One of the key regulators of blood pressure is the renin-angiotensin aldosterone system (RAAS).
Allison M. Bell, Diane Nykamp
core +1 more source
The Journal of Clinical Hypertension, 2021 Angiotensin‐receptor blockers are often considered insufficiently efficacious in reducing blood pressure. However, newer angiotensin‐receptor blockers may be more effective than the older ones.
Ji‐Guang Wang +6 more
doaj +1 more source
, 2010 Current hypertension guidelines recommend using two antihypertensive agents when blood pressure (BP) control is not achieved with one single agent. Objective: This study was designed to assess the antihypertensive benefit of the olmesartan medoxomil 40mg/
Melani L +5 more
core +1 more source
Metal‐Catalyzed Transformations of Carbon Dioxide Toward the Production of Commodity Chemicals
Advanced Synthesis &Catalysis, Volume 368, Issue 17, 1 September 2026.This perspective highlights how transition‐metal catalysis can enable the synthesis of economically attractive CO2‐derived commodity chemicals. By transforming waste CO2 into acrylic acid, cyclic carbonates, and other valuable products, these strategies provide a practical route for simultaneous CO2 sequestration and valorization, helping to align ...
Chaodi Dai +2 more
wiley +1 more source
Clinical efficacy of olmesartan medoxomil.
, 2003 Olmesartan medoxomil is a new angiotensin-II receptor antagonist for the treatment of hypertension. Olmesartan medoxomil is a pro-drug that is de-esterified to the active metabolite, olmesartan. Olmesartan has a dual method of elimination, with about 60%
Brunner HR, Laeis P
core +1 more source
Кардиоваскулярная терапия и профилактика, 2011 Angiotensin II receptor blockers (ARBs) have been available in the United Statessince 1995. These agents have demonstrated antihypertensive efficacy at least similar to that of agents from other antihypertensive classes.
M. Greathouse
doaj +1 more source